title: The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide.
abstract: Although lymphomas account for almost half of blood-derived cancers that are diagnosed each year, the causes of new cases are poorly understood, as reflected by the relatively few risk factors established. Galectin-1, an immunoregulatory ß-galactoside-binding protein, has been widely associated with tumor-immune escape. The aim of the present work was to study the relationship between tumor growth rate, aggressiveness, and response to cyclophosphamide (Cy) therapy with regard to Gal-1 expression in murine T-cell lymphoma models. By means of a disruptive selection process for tumor growth rate, we generated two lymphoma variants from a parental T-cell lymphoma, which have unique characteristics in terms of tumor growth rate, spontaneous regression, metastatic capacity, Gal-1 expression and sensitivity to Cy therapy. Here, we show that Gal-1 expression strongly correlates with tumor growth rate, metastatic capacity and response to single-dose Cy therapy in T-cell lymphoma models; this association might have important consequences for evaluating prognosis and treatments of this type of tumors.
authors.affiliation: Instituto de Genética Experimental, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe 3100, S2002KTR, Rosario, Argentina.
authors.forename: Mariano F
authors.initials: MF
authors.lastname: Zacarías Fluck
authors.forename: Leonardo
authors.initials: L
authors.lastname: Hess
authors.forename: Mariana
authors.initials: M
authors.lastname: Salatino
authors.forename: Diego O
authors.initials: DO
authors.lastname: Croci
authors.forename: Juan C
authors.initials: JC
authors.lastname: Stupirski
authors.forename: Ricardo J
authors.initials: RJ
authors.lastname: Di Masso
authors.forename: Eduardo
authors.initials: E
authors.lastname: Roggero
authors.forename: Gabriel A
authors.initials: GA
authors.lastname: Rabinovich
authors.forename: O Graciela
authors.initials: OG
authors.lastname: Scharovsky
mesh_terms: D000818:Animals; D015704:CD4 Antigens / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D051858:Forkhead Transcription Factors / Q000378:metabolism; D037483:Galectin 1 / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007165:Immunosuppression Therapy; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D051379:Mice; D009362:Neoplasm Metastasis; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000473:pathology
chemical_list: D015704:CD4 Antigens; D051858:Forkhead Transcription Factors; C498833:Foxp3 protein, mouse; D037483:Galectin 1; D053645:Interleukin-2 Receptor alpha Subunit; D003520:Cyclophosphamide